MX2022013065A - Sistemas y metodos para coordinar la manufactura de celulas para inmunoterapia especifica de acuerdo al paciente. - Google Patents

Sistemas y metodos para coordinar la manufactura de celulas para inmunoterapia especifica de acuerdo al paciente.

Info

Publication number
MX2022013065A
MX2022013065A MX2022013065A MX2022013065A MX2022013065A MX 2022013065 A MX2022013065 A MX 2022013065A MX 2022013065 A MX2022013065 A MX 2022013065A MX 2022013065 A MX2022013065 A MX 2022013065A MX 2022013065 A MX2022013065 A MX 2022013065A
Authority
MX
Mexico
Prior art keywords
patient
cell
therapy product
expansion
cell therapy
Prior art date
Application number
MX2022013065A
Other languages
English (en)
Inventor
Anne Brooks
Steve Macrides
Kristin Lanzi
Original Assignee
Iovance Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iovance Biotherapeutics Inc filed Critical Iovance Biotherapeutics Inc
Publication of MX2022013065A publication Critical patent/MX2022013065A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/08—Logistics, e.g. warehousing, loading or distribution; Inventory or stock management
    • G06Q10/083—Shipping
    • G06Q10/0832—Special goods or special handling procedures, e.g. handling of hazardous or fragile goods
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Business, Economics & Management (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Business, Economics & Management (AREA)
  • Economics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Human Resources & Organizations (AREA)
  • Operations Research (AREA)
  • Theoretical Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Tourism & Hospitality (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Development Economics (AREA)
  • Entrepreneurship & Innovation (AREA)

Abstract

Un método para coordinar la manufactura de un producto de terapia celular expandido para un paciente puede incluir recibir una solicitud de pedido de células para expandir el producto de terapia celular para el paciente; generar un identificador específico del paciente o un identificador de orden de célula asociado con la solicitud de orden de célula; e iniciar un proceso para expandir el producto de terapia celular de al menos parte de un tumor sólido obtenido del paciente. Si los parámetros de aceptación para el producto de terapia celular de expansión no cumplen con ciertos criterios de aceptación en un segundo momento posterior al primer momento en el proceso de expansión, se determina si se vuelve a realizar la expansión del producto de terapia celular usando la técnica de expansión celular es posible desde el primer punto de tiempo basado en los parámetros de aceptación en el segundo punto de tiempo. Si es posible repetir la expansión, los eventos de tratamiento del paciente que usan el producto de terapia celular expandida se reprograman.
MX2022013065A 2020-04-22 2021-04-22 Sistemas y metodos para coordinar la manufactura de celulas para inmunoterapia especifica de acuerdo al paciente. MX2022013065A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063013942P 2020-04-22 2020-04-22
US202163155711P 2021-03-02 2021-03-02
US202163159806P 2021-03-11 2021-03-11
PCT/US2021/028709 WO2021216920A1 (en) 2020-04-22 2021-04-22 Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

Publications (1)

Publication Number Publication Date
MX2022013065A true MX2022013065A (es) 2022-12-08

Family

ID=76138096

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013065A MX2022013065A (es) 2020-04-22 2021-04-22 Sistemas y metodos para coordinar la manufactura de celulas para inmunoterapia especifica de acuerdo al paciente.

Country Status (12)

Country Link
US (5) US20210335467A1 (es)
EP (1) EP4139440A1 (es)
JP (1) JP2023524639A (es)
KR (1) KR20230037069A (es)
CN (1) CN115997008A (es)
AU (1) AU2021258257A1 (es)
BR (1) BR112022021020A2 (es)
CA (1) CA3176356A1 (es)
IL (1) IL297442A (es)
MX (1) MX2022013065A (es)
TW (1) TW202206592A (es)
WO (1) WO2021216920A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041678A1 (en) * 2016-10-26 2018-05-03 Iovance Biotherapeutics, Inc. Restimulation of cryopreserved tumor infiltrating lymphocytes
US11024160B2 (en) * 2016-11-07 2021-06-01 Nio Usa, Inc. Feedback performance control and tracking
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
IL294098A (en) 2019-12-20 2022-08-01 Instil Bio Uk Ltd Devices and methods for isolating lymphocytes infiltrating tumors and their use
WO2023225048A1 (en) * 2022-05-17 2023-11-23 Synthego Corporation Systems and methods for engageable platforms and modules for cell processing
US20240086416A1 (en) * 2022-09-09 2024-03-14 Honeywell International Inc. Methods and systems for integrating external systems of records with final report
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
US7922073B2 (en) * 1997-10-21 2011-04-12 Carlos De La Huerga Vial printing method and apparatus
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
MXPA01006422A (es) 1998-12-23 2002-06-04 Pfizer Inc Abgenix Inc Anticuerpos monoclonales humanos de ctla-4.
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US7034121B2 (en) 2000-01-27 2006-04-25 Genetics Institue, Llc Antibodies against CTLA4
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
NZ553687A (en) 2000-03-30 2010-03-26 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
WO2002037938A2 (en) * 2000-10-24 2002-05-16 Oncosis Llc Method and device for selectively targeting cells within a three -dimensional specimen
EP1353701B1 (en) 2000-10-31 2011-12-21 PR Pharmaceuticals, Inc. Methods for producing compositions for enhanced delivery of bioactive molecules
SI1407044T2 (en) 2000-12-01 2018-03-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Small RNA molecules that mediate RNA interference
US6615092B2 (en) * 2001-03-05 2003-09-02 Dell Products L.P. Method, system and facility for controlling resource allocation within a manufacturing environment
US20030175242A1 (en) * 2001-09-17 2003-09-18 Micheal Gruenberg Cell therapy system
DE10161064A1 (de) 2001-12-12 2003-07-03 Siemens Ag System und Verfahren zur Kommunikation zwischen Softwareapplikationen, insbesondere MES-Applikationen
US20030149608A1 (en) 2002-02-06 2003-08-07 Kall Jonathan J. Suite of configurable supply chain infrastructure modules for deploying collaborative e-manufacturing solutions
DK2330181T3 (en) * 2002-04-08 2019-03-25 Octane Biotech Inc AUTOMATED Tissue Manipulation System
JP2005529873A (ja) 2002-04-12 2005-10-06 メダレックス インコーポレイテッド Ｃｔｌａ−４抗体を使用した治療の方法
US9565275B2 (en) 2012-02-09 2017-02-07 Rockwell Automation Technologies, Inc. Transformation of industrial data into useful cloud information
US7076312B2 (en) 2002-08-02 2006-07-11 Fisher-Rosemount Systems, Inc. Integrated electronic signatures for approval of process control and safety system software objects
WO2004021995A2 (en) 2002-09-06 2004-03-18 The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
PT3284753T (pt) 2002-10-17 2020-05-04 Genmab As Anticorpos monoclonais humanos contra cd20 para utilização no tratamento da esclerose múltipla
US7962361B2 (en) 2002-11-07 2011-06-14 Novitaz Customer relationship management system for physical locations
US20060246123A1 (en) 2003-03-12 2006-11-02 Eli Gilboa Oligonucleotide mimetics
EP3450538B1 (en) 2003-10-08 2021-08-25 Wilson Wolf Manufacturing Corporation Cell culture methods and devices utilizing gas permeable materials
KR100845354B1 (ko) 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항－ｃｔｌａ－4 항체의 용도
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
EP1781083A4 (en) 2004-06-18 2009-09-09 Univ California SEQUENCES OF BRASSICA INDEHISCENT1
US8239749B2 (en) 2004-06-25 2012-08-07 Apple Inc. Procedurally expressing graphic objects for web pages
EP1793858A4 (en) 2004-09-08 2008-12-10 Univ Ohio State Res Found HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
CN101238218A (zh) * 2005-05-20 2008-08-06 维克西斯公司 初级细胞的转导
CA3201163A1 (en) 2005-07-01 2007-01-11 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US20070143165A1 (en) 2005-08-12 2007-06-21 John Roberts Customer relationship management system and method
EP1954311A4 (en) 2005-12-07 2009-12-23 Medarex Inc CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY
US20100143918A1 (en) 2007-01-19 2010-06-10 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
AU2007241023B2 (en) 2006-03-30 2013-11-28 University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
JP2008066402A (ja) 2006-09-05 2008-03-21 Fujifilm Corp 撮像素子および撮像装置
CA2666509C (en) 2006-10-16 2017-05-09 Hospira, Inc. System and method for comparing and utilizing activity information and configuration information from multiple medical device management systems
US8041444B2 (en) 2006-12-22 2011-10-18 Harris Stratex Networks Operating Corporation Intelligent production station and production method
ES2616355T3 (es) 2007-06-18 2017-06-12 Merck Sharp & Dohme B.V. Anticuerpos para el receptor humano de muerte programada PD-1
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP3741851A1 (en) 2007-10-18 2020-11-25 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
EP2240204A1 (en) 2008-02-04 2010-10-20 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
JP2012500013A (ja) 2008-08-18 2012-01-05 マックス−プランク−ゲゼルシャフト ツール フェルデルンク デル ヴィッセンシャフテン エー．ファウ． Ｈｓｐ９０阻害剤に対する感受性
HRP20240240T1 (hr) 2008-12-09 2024-04-26 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
CA2744236C (en) 2009-02-12 2021-03-16 Cell Signaling Technology, Inc. Mutant ros expression in human cancer
KR101312053B1 (ko) 2009-02-25 2013-09-25 (주)리치스톤 스크롤 유체기계
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012033537A1 (en) * 2010-09-08 2012-03-15 Nodality, Inc. Benchmarks for normal cell identification
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
JP2013512694A (ja) 2009-12-08 2013-04-18 ウィルソン ウォルフ マニュファクチャリング コーポレイション 養子細胞療法のための細胞を培養する方法
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US9783578B2 (en) 2010-06-25 2017-10-10 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012065086A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
AU2012288413B2 (en) 2011-07-24 2016-10-13 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
TW201312117A (zh) 2011-07-28 2013-03-16 Univ Pennsylvania 用以診斷與漿液相關之腫瘤細胞的症狀及特性的方法及試劑
AU2012324644B2 (en) 2011-10-21 2014-08-28 Cell Medica Limited Device for the aseptic expansion of cells
CA2854832C (en) 2011-11-07 2023-05-23 Ingenuity Systems, Inc. Methods and systems for identification of causal genomic variants
DK2785375T3 (da) 2011-11-28 2020-10-12 Merck Patent Gmbh Anti-pd-l1-antistoffer og anvendelser deraf
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2822957A1 (en) 2012-03-07 2015-01-14 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
CA2868408A1 (en) 2012-03-29 2013-10-03 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
US20140088985A1 (en) 2012-03-30 2014-03-27 Elizur Corporation Providing healthcare solutions and workflow management
US20150056193A1 (en) 2012-04-18 2015-02-26 Cell Signaling Technology, Inc. Egfr and ros1 kinase in cancer
CA2872504A1 (en) 2012-05-18 2013-11-21 Wilson Wolf Manufacturing Corporation A static animal cell culture and cell recovery
EP3401402B1 (en) 2012-06-08 2020-10-14 Alkermes Pharma Ireland Limited Ligands modified by circular permutation as agonists and antagonists
IL302514A (en) 2012-06-11 2023-07-01 Wilson Wolf Mfg Corporation Improved cell culture methods for stress cell therapy
US20140244351A1 (en) 2013-02-28 2014-08-28 Single Funnel Pty Ltd Customer relationship management (crm) systems
AU2013379772B2 (en) 2013-03-01 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive T cells from tumor
EP3628322A1 (en) 2013-03-01 2020-04-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
AU2014262481A1 (en) 2013-05-10 2015-11-26 Foundation Medicine, Inc. Analysis of genetic variants
US20140372147A1 (en) 2013-06-13 2014-12-18 NaviNet, Inc. Systems, methods, and environment for identification and processing of medical events
WO2014210036A1 (en) 2013-06-24 2014-12-31 Wilson Wolf Manufacturing Corporation Closed system device and methods for gas permeable cell culture process
HUP1300432A2 (hu) 2013-07-10 2015-01-28 Tamas Kardos Downhill kerékpár szerkezet javított felfüggesztéssel
AU2014316682B2 (en) 2013-09-06 2018-11-22 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
EP3041828B1 (en) 2013-09-06 2018-05-23 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
HRP20221262T1 (hr) 2013-09-13 2022-12-09 Beigene Switzerland Gmbh Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava
US10233425B2 (en) 2013-09-16 2019-03-19 The Trustees Of The University Of Pennsylvania CD137 enrichment for efficient tumor infiltrating lymphocyte selection
US9678505B2 (en) 2013-10-14 2017-06-13 Invensys Systems, Inc. Line management in manufacturing execution system
CN112080467A (zh) 2014-03-20 2020-12-15 H.李莫菲特癌症中心研究院 用于过继细胞疗法的肿瘤浸润淋巴细胞
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
MX370018B (es) * 2014-04-25 2019-11-28 Bluebird Bio Inc Metodos mejorados para la elaboracion de terapias celulares adoptivas.
US20170107490A1 (en) 2014-06-11 2017-04-20 Polybiocept Ab Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
CA2963362A1 (en) 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
CA2986765A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
US10108965B2 (en) 2015-07-14 2018-10-23 Ujet, Inc. Customer communication system including service pipeline
MX2018010362A (es) 2016-02-29 2019-03-28 Found Medicine Inc Metodos y sistemas para evaluar carga mutacional de tumores.
WO2017210677A1 (en) 2016-06-03 2017-12-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA (PGC1α) AGONISTS TO IMPROVE EX VIVO EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS)
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
JP7265989B2 (ja) 2016-10-25 2023-04-27 ウロゲン ファーマ リミテッド 体腔の免疫調節治療
CA3041678A1 (en) 2016-10-26 2018-05-03 Iovance Biotherapeutics, Inc. Restimulation of cryopreserved tumor infiltrating lymphocytes
JP2019534308A (ja) 2016-11-10 2019-11-28 ネクター セラピューティクス 免疫療法的腫瘍治療方法
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
CN110383385B (zh) 2016-12-08 2023-07-25 生命科技股份有限公司 从肿瘤样品中检测突变负荷的方法
CN110167598A (zh) 2017-01-10 2019-08-23 尼克塔治疗公司 Tlr激动剂化合物的多臂聚合物缀合物以及相关的免疫治疗方法
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
WO2018204760A1 (en) 2017-05-05 2018-11-08 David Weiner Ctla4 antibodies and vaccine combinations and use of same for immunotherapy
CN110662762A (zh) 2017-05-24 2020-01-07 诺华股份有限公司 抗体细胞因子移植蛋白和用于治疗癌症的方法
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
EP3661955A4 (en) 2017-08-03 2021-05-26 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CN111315403A (zh) * 2017-09-15 2020-06-19 凯德药业股份有限公司 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和***
CA3102859A1 (en) 2018-07-03 2020-01-09 Gilead Sciences, Inc. Antibodies that target hiv gp120 and methods of use
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
US20210038684A1 (en) 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy

Also Published As

Publication number Publication date
US20220059202A1 (en) 2022-02-24
TW202206592A (zh) 2022-02-16
US20220122707A1 (en) 2022-04-21
IL297442A (en) 2022-12-01
WO2021216920A1 (en) 2021-10-28
CA3176356A1 (en) 2021-10-28
AU2021258257A1 (en) 2022-11-10
CN115997008A (zh) 2023-04-21
US20210407639A1 (en) 2021-12-30
JP2023524639A (ja) 2023-06-13
US11631483B2 (en) 2023-04-18
EP4139440A1 (en) 2023-03-01
US20210335467A1 (en) 2021-10-28
US20210407640A1 (en) 2021-12-30
KR20230037069A (ko) 2023-03-15
BR112022021020A2 (pt) 2023-02-14

Similar Documents

Publication Publication Date Title
MX2022013065A (es) Sistemas y metodos para coordinar la manufactura de celulas para inmunoterapia especifica de acuerdo al paciente.
Palladini et al. In silico modeling and in vivo efficacy of cancer-preventive vaccinations
EP1504403A4 (en) TOMOGRAPHIC RECONSTRUCTION OF SMALL OBJECTS USING A "PRIORI" KNOWLEDGE
EP4325984A3 (en) System and method for beam adjustment request
WO2008058248A3 (en) Apparatus and method for introducing particles using a radio frequency quadrupole linear accelerator for semiconductor materials
SG11201906166YA (en) Blockchain service acceptance and consensus method and devices
MX2021005021A (es) Proceso para producir celulas t geneticamente modificadas.
EP1315055A3 (en) System and method for function block execution order generation
RU2007105501A (ru) Преобразование аудиканалов
WO2020035089A3 (en) System and method for blockchain-based decentralized application development
CN107679863A (zh) 一种区块链***及快速验证区块的方法
WO2019228551A3 (en) System and method for registering subscribable states in blockchain
MX2021008140A (es) Protocolo basado en ultrasonido para operar un dispositivo implantable.
MX2023004330A (es) Generador de audio y métodos para generar una señal de audio y entrenamiento de un generador de audio.
WO2019228553A3 (en) System and method for registering subscribable sub-states in blockchain
WO2023077015A3 (en) Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
WO2021077086A8 (en) Synthesizing audio of a venue
EP3832465A3 (en) Methods, systems, articles of manufacture, and apparatus to optimize thread scheduling
MX2022006638A (es) Producción de 212pb altamente purificados.
CN110176988A (zh) 保证冗余执行体加密行为一致的装置及方法
AR121916A1 (es) Sistemas y métodos para coordinar la manufactura de células para inmunoterapia paciente específica
EP4236189A3 (en) Distributed biometric comparison framework
CN106559212A (zh) 数据处理方法和装置
US6293291B1 (en) Method and apparatus for the treatment of objects, preferably wafers
AU2003230803A1 (en) Systems and method for generating an image